KRAS and glioblastoma: To overcome KRAS-driven resistance to EGFR inhibitors, co-inhibition of EGFR and DDR1/BCR-ABL has previously demonstrated synergistic efficacy in retarding cell growth and inducing apoptosis in tumouroids of patient-derived recurrent GBM [60].